This growth is driven by advancements in data-driven clinical trials and the integration of digital health technologi ...

Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF. Visit NAP.edu/10766 to get more information about this ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

NeuroXT, a leading biotechnology company specializing in AI-driven neuroimaging biomarkers, today announced the successful completion of its initial collaborative research with Beth Israel Deaconess ...

According to MarketsandMarkets™, the Cancer Biomarkers Market is projected to grow from about USD 28.25 billion in 2026 to ...

CNW/ - The Colorectal Cancer Resource & Action Network (CCRAN) proudly announces its 4th Annual Pan-Tumour Biomarkers Conference, to be held virtually on ...

Bristol Myers Squibb’s Ann Mongan highlighted the U.S. FDA’s cautious stance on using biomarkers as surrogate endpoints in drug approvals, citing recent examples like Regenxbio’s gene therapy setback.

First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally The growing cancer burden and ...